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Abstract
Purpose of review—The role of bone morphogenetic proteins (BMPs) in vasculogenesis is still
not well understood, despite many recent developments in this area of research. In this review, we
discuss the most recent studies that identify new critical mechanisms through which BMP
signaling acts with a focus on angiogenesis.
Recent findings—New evidence brought to light over the last few years suggests that BMP-
binding proteins, formerly thought of as antagonists, can also increase BMP activity under certain
conditions. It has also recently been determined that components of the extracellular matrix are
involved in the BMP signaling pathways that regulate angiogenesis. Through the BMP pathway,
myosin-X and cyclooxygenase 2 serve as target genes that have been determined to play a role in
blood vessel formation. BMPs also conduct Smad-independent signaling and crosstalk with other
pathways. Finally, BMPs have been shown to play an antiangiogenic role in specific settings.
Summary—Better understanding of the BMP signaling pathway and its regulators can have
potentially great effects on therapeutic strategies from cardiovascular disease to cancer.
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Introduction
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor β (TGFβ)
superfamily of extracellular signaling proteins and were initially described for their ability to
induce ectopic bone and cartilage formation [1]. BMPs are required for mesoderm formation
and consequently for the development of all mesodermally derived tissues, including blood
vessels [2,3]. Mice defective in Smad 1 or Smad 5 (integral components of the BMP
signaling cascade) die in utero due to defective vasculature formation [4–7]. After birth,
BMPs are critical for maintenance of angiogenesis through regulation of vascular
endothelial growth factor (VEGF) [8].
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A variety of regulatory mechanisms have been described and many excellent reviews have
been published on the BMP signaling pathway. However, new layers of complexity are
constantly being added to the network of regulators and effectors underlying the BMP
pathway, reflecting the fine-tuning of this signaling pathway to specific developmental
requirements. This review focuses on recent advances in our knowledge of the regulation of
angiogenesis by BMPs.
New roles for extracellular bone morphogenetic protein antagonists
Numerous extracellular BMP antagonists have been described; on the basis of protein
sequence alignment, these can be categorized into subgroups, including noggin, the chordin
family, twisted gastrulation, and the Dan family [9]. BMP antagonists bind with high
affinity to BMPs and have been shown to prevent the interaction of BMP proteins with their
cognate receptors. However, recently published studies have also described ‘agonist’
activities of several formerly known BMP antagonists. For example, twisted gastrulation,
when expressed at high levels in the presence of xolloid, exerts a ‘pro-BMP’ signal on
developing Xenopus embryos [10]. In Drosophila, the secreted BMP antagonist short
gastrulation (Sog, homolog of chordin) is also capable of enhancing signaling by
transporting BMPs through tissues [11]. Determining the circumstances under which a
BMP-binding protein acts as an antagonist or agonist has been quite a challenge. However,
accumulating data suggest that some of the factors that help determine the effect on BMP
signaling include concentration of the binding protein, the identity of the BMP ligand
involved, and the developmental stage and characteristics of the cell types involved. The
evidence supporting a dual role for two traditional BMP antagonists, BMP endothelial cell
precursor-derived regulator (BMPER) and gremlin, are described below.
Bone morphogenetic protein endothelial cell precursor-derived regulator
BMPER, also known as crossveinless-2 (CV2), is attributed both pro and anti-BMP
signaling effects [12–17], although the mechanism behind this dual action is uncertain.
Growing evidence suggests that the concentration of BMPER relative to BMP may
determine the nature of its effect on signaling. Studies from our laboratory demonstrate that
the ratio of BMP4 to BMPER modifies the intracellular response to BMP4. Low BMPER
concentrations lead to an increase in p-Smad1/5/8 levels, whereas excess BMPER inhibits
BMP4-mediated phosphorylation of Smads (Kelley et al., in preparation) (Fig. 1a).
Similarly, in Drosophila posterior crossvein (PCV) formation experiments, moderately
increasing expression of a BMPER transgene results in a slight gain in signaling (occasional
formation of additional veins), whereas continuing to increase expression levels eventually
blocks PCV formation, similar to knocking-out BMPER in this system [18••]. Similar dose-
dependent effects of BMPER have been observed in several in-vivo angiogenesis assays,
including sprouting and migration of human umbilical vein endothelial cells (HUVECs),
development of chick embryo chorioallantoic membrane capillary networks, and invasion of
mouse subcutaneous endothelial cells in Matrigel plug experiments. In all these cases, low
BMPER concentrations enhance sprouting and vasculature formation, whereas high
concentrations inhibit it. In addition, silencing endogenous BMPER or BMP4 inhibited
HUVEC cell sprouting and migration, indicating that their proangiogenic function in these
assays is dependent on each other’s presence [19••].
Different hypotheses have been put forward to explain BMPER’s ability to act as either an
agonist or antagonist of BMP signaling. According to one model, when BMPER binds to
BMP2 it overlaps with the BMP2 epitope that interacts with the type II receptor interaction
while at the same time covering most of the hydrophobic patch of the epitope required for
type I receptor binding [20]. Interestingly, in alkaline phosphatase assays and RNA
injections in zebrafish embryos, BMPER mutants that fail to interact with BMP2 lose their
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anti-BMP activity (dorsalization), whereas the weak pro-BMP action observed in zebrafish
(weak ventralization) appears independent of BMP–BMPER interaction. These results lead
to the conclusion that blocking BMP’s interaction with its receptor is the inhibitory
mechanism used by BMPER under these circumstances, whereas BMPER’s pro-BMP
effects appear to be independent of BMP (Fig. 1b). Other studies, however, suggest that the
mechanism of BMPER’s dual action may not be as simple as blocking the interaction of
BMP with its receptor. In Drosophila, CV2 binds Dpp (BMP2/4 homolog) and Gbb (BMP7
homolog) as well as the receptor thickveins (BMPR-I homologous), indicating that a ligand–
receptor interaction is still possible in this case even in the presence of BMPER.
Furthermore, Dpp can interact with both CV2 and BMPR-IB simultaneously [18••]. Another
indication that there may be one or more mechanism involved in BMPER’s regulation of
BMP signaling comes from studies carried out in our laboratory. We have data indicating
that BMPER inhibits BMP signaling in mouse intraembryonic endothelial cells (MECs) by
inducing clathrin-mediated endocytosis of the complex BMPER–BMP–BMPR (Kelley et
al., in preparation) (Fig. 1a).
Mathematical models that take into account the calculated dissociation constant values for
different BMPs, BMPER, and the receptors suggest that BMPER might display different
responses (i.e. agonist versus antagonist) depending on the isoform of BMP with which it is
interacting. In S2 cells, excess BMPER blocks Dpp and Gbb signaling, whereas reducing
endogenous BMPER by RNAi increases Dpp signaling but reduces Gbb signaling by 20–
30% [18••]. Surprisingly though, in the early Drosophila embryo, where a different set of
BMP ligands act, loss of endogenous BMPER actually expands BMP signaling, opposite to
the effects of BMPER loss in the PCV [18••]. Therefore, BMPER concentration and the type
of BMP present appear to determine whether BMPER promotes or inhibits BMP signaling.
This could be explained by a model whereby BMPER, at moderate levels, could move
BMPs from the extracellular space onto receptors via the complex BMP–BMPER–BMPR,
whereas, at higher levels, BMPER antagonizes signaling by sequestering BMPs in the
complex (Fig. 1a).
Yet another potential mechanism of action recently proposed involves BMPER antagonism
of chordin actions through direct interaction. In Xenopus embryos BMPER acts as a local
BMP feedback inhibitor. However, when chordin levels are increased, BMPER can exert
pro-BMP effects via some form of chordin antagonism, whereas loss of BMPER enhanced
overexpressed chordin anti-BMP activity (Fig. 1b) [21•].
Gremlin
Gremlin, a potent BMP inhibitor, exerts its anti-BMP signaling effects by binding BMPs in
such a way that interaction with BMP receptors is no longer possible (Fig. 1b) [22]. Gremlin
can also inhibit BMP signaling by interacting with the BMP4 precursor protein thereby
preventing the secretion of mature BMP4 (Fig. 1c) [23]. However, similar to BMPER and
other so-called BMP antagonists, gremlin has also been shown to be capable of
proangiogenic activity, in this case though, through BMP-independent mechanisms. In
subcutaneous microvascular endothelial cells, gremlin interacts with an unknown membrane
protein to induce the phosphorylation of focal adhesion kinase, paxillin, and extracellular
signal-regulated kinase (ERK)1/2, resulting in a proangiogenic effect (Fig. 1c) [24•].
Gremlin can also specifically upregulate angiopoietin-1 (Ang-1) expression (but not Ang-2,
Tie-2 receptor, or VEGFA) in endothelial cells, resulting in a proangiogenic effect that
appears to be mediated via the activation of nuclear factor-kappa B (NF-κB) [25]. As
mentioned, these interactions are not influenced by BMP4.
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Extracellular matrix components involved in bone morphogenetic protein
signaling
Although extracellular matrix (ECM) proteins are often considered to be just ‘scaffolding’
outside the cell, recent reports have uncovered a crucial role for them in the regulation of
TGFβ signaling and, more recently, BMPs in the vascular system. ECM proteins immobilize
TGFβ proteins in the extracellular space before they have a chance to bind to receptors on
the cell surface, thereby regulating the bioavailability of TGFβ [26]. A similar relationship
between BMP signaling and the ECM component matrix gamma-carboxyglutamate protein
(MGP) has also been described [27]. MGP, an inhibitor of tissue and vascular calcification,
is expressed in endothelial cells where it appears to play a key role in maturation of
vasculature. In bovine aortic endothelial cells (BAECs), MGP can increase expression of
VEGF by enhancing TGFβ signaling through the receptor activin receptor-like kinase 1
(ALK1) [28]. However, in the same cells, a progressive increase of MGP levels ceases to be
stimulatory and instead turns inhibitory. It has been suggested that a novel regulatory
pathway involving BMPs may mediate this biphasic effect of MPG. BMP2 and BMP4
induce the expression of ALK1 in a dose-dependent fashion, and ALK1, when activated by
TGFβ, induces expression of MGP in addition to VEGF. Interestingly, low-to-intermediate
doses of MGP enhance ALK1 signaling, thereby providing positive feedback to this system.
However, when the concentration of MGP increases, it binds and inhibits BMP2 and BMP4,
thus providing negative feedback for BMP signaling, which ultimately leads to a decline in
ALK1 and VEGF expression (Fig. 2a) [29]. These findings demonstrate that the relationship
between BMP and the ECM protein MGP is critical in the regulation of endothelial growth
and proliferation and, as such, tight feedback loops exist within this pathway to ensure
appropriate cellular responses.
Myosin-X and cyclooxygenase 2 are bone morphogenetic protein target
genes involved in blood vessel formation
BMPs are well known potent angiogenic factors in mouse embryonic stem cells [15,30],
Xenopus embryos [31], as well as in-vitro assays [32]. In addition, BMP2 and BMP4 can
enhance neovascularization in tumors [33–35]. However, only VEGF and Id1 had been
identified as angiogenic downstream BMP target genes [8,32], rendering the mechanisms by
which BMPs induce vascular development relatively unknown. Using information gleaned
from gene expression analysis of BMP-stimulated MECs, our laboratory recently identified
two new direct BMP target genes involved in angiogenesis. The first is cyclooxygenase 2
(Cox2), which catalyses the conversion of arachidonic acid to prostaglandins. BMP6 induces
Cox2 expression as well as production of prostaglandins in a Cox2-dependent fashion. We
found that Cox2 mediates BMP6-induced endothelial cell proliferation, migration, and
network assembly as well as microvessel outgrowth in aortic rings [36]. These results are in
agreement with the association of Cox2 with several physiologic and pathologic pathways
that participate in angiogenesis, inflammation, and invasiveness [37,38].
In addition to Cox2, we also demonstrated that both BMP6 and BMP2 are powerful inducers
of myosin-X (MyoX) expression, an unconventional myosin critical for filopodial
formation. BMP6-mediated induction of MyoX is necessary for filopodial formation, cell
alignment, directed migration, and tube formation in MECs. In addition, MyoX colocalizes
with the BMP receptor ALK6 in the filopodia, and is necessary for activation of Smads,
suggesting that MyoX mediates localization and amplification of BMP responses in
endothelial cells [39•].
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Bone morphogenetic protein Smad-independent signaling and crosstalk
with other pathways
Traditionally, BMP signaling pathways have been reported to involve Smad phosphorylation
and direct transcriptional regulation of target genes. However, recent studies [40,41] have
identified new routes of BMP signaling as well as modulation of BMP signaling by crosstalk
with other pathways.
In addition to the canonical Smad phosphorylation pathway, BMPs can also activate Erk,
Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) pathways
to influence embryonic development and bone formation [41,42]. Recently, Erk
phosphorylation in endothelial cells was implicated for BMP4-induced capillary sprouting
(Fig. 2b) [43•]. Although BMP4 activates Erk phosphorylation in this assay, strikingly,
Smad-mediated signaling is not required for sprouting. However, Smad and Erk pathways
do communicate through signal crosstalk as overexpression of the inhibitory Smad6 inhibits
Erk phosphorylation and Erk-induced capillary sprouting (Fig. 2b) [43•].
Furthermore, it is now well accepted that Erk/MAPK can regulate Smad-mediated signaling.
However, the end result of this Erk pathway signaling appears to depend on the cell type
involved and target gene specificity, with both enhanced and inhibitory Smad activity being
reported by various groups [44–46]. For example, Smurf1 (an E3 ubiquitin ligase)
selectively recognizes the MAPK-phosphorylated linker domain of Smad1 and
polyubiquitinates the protein, leading to its degradation and subsequent inhibition of activity
[47]. However, a recent study [48•] indicates that Smad1 degradation requires subsequent
glycogen synthase kinase 3 (GSK3) phosphorylation in the linker domain, and pSmad
activity can be rescued by Wnt signaling inhibition of GSK3 (Fig. 2c). Little is known about
the effects of this mode of Smad regulation in angiogenic processes.
Finally, BMP signaling can also be mediated through the regulation of micro-RNA
(miRNA) maturation [49••]. miRNAs are endogenous, small, noncoding RNAs that regulate
gene expression at the posttranscriptional level, and recent findings provide evidence of a
direct link between BMP/TGFβ signaling and miRNA regulation in human vascular smooth
muscle cells. Upon stimulation, phosphorylated R-Smads physically interact with the
primary miRNA processing machinery in the nucleus. This interaction leads to an increase
in mature miRNAs, particularly miR-21, through a not yet defined mechanism (Fig. 2d).
This new mechanism of Smad-mediated BMP signaling is receiving a lot of attention
because of the fact that recent research shows that miRNAs can regulate heart and vascular
development [50], opening up exciting new therapeutic possibilities in the treatment of
cardiovascular diseases.
Bone morphogenetic protein: the antiangiogenic role
As well known as BMPs are for their ability to stimulate angiogenic processes, several
reports have shown that BMPs can also play a role in inhibiting angiogenesis. In a mouse
model of hypoxia-induced neovascularization of the retina, BMP2 and BMP4 are
downregulated soon after the onset of hypoxia, a process that appears necessary for
subsequent tissue repair and neovascularization [51]. In an in-vitro angiogenesis assay with
endothelial cells, BMP4 was found to exert an antiangiogenic influence, which could be
reversed by the addition of chordin-like 1 [52]. In the vasculature of the rat papillary
membrane (a transient vasculature in developing mammals), BMP4 induces apoptosis and
regression. In addition, lens-conditioned medium obtained from rats induces apoptosis in
endothelial cells and inhibits endothelial tubulogenesis, effects that can be blocked by both
Noggin and the BMP4-specific neutralizing antibody [53]. However, not all endothelial cells
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undergo apoptosis when treated with BMP4. Although capillary and venous cells appear to
be sensitive to the antiangiogenic effects of BMP4, coronary arterial cells are immune,
suggesting that differential expression of inhibitory Smad proteins protects arterial
endothelial cells from BMP4 apoptosis [54].
BMP9 and BMP10 are also capable of exerting antiangiogenic effects, potently inhibiting
basic fibroblast growth factor-stimulated proliferation and migration of BAECs, VEGF-
induced formation of tubular endothelial cell structures in a bone-explant angiogenesis assay
[55], and endothelial cell migration and growth in a mouse sponge angiogenesis assay in
response to basic fibroblast growth factor [56,57•]. In this assay, BMP9 not only inhibits
sprouting angiogenesis but also induces destabilization of already formed vessels [57•].
Conclusion
The role of BMPs in embryonic development has been studied extensively in the past
decades, but only recently has their role in vasculogenesis been recognized. The presence of
both positive and negative BMP-mediated signaling responses in endothelial cells requires
further dissection of the mechanisms by which BMPs participate in the control of
angiogenesis. Understanding the role of BMPs in blood vessel formation may open up new
therapeutic avenues in vascular disease.
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Figure 1. Proposed model for bone morphogenetic protein endothelial cell precursor-derived
regulator and gremlin actions as bone morphogenetic protein agonists or antagonists
(a) (Yellow) Moderate levels of BMPER (ratio BMPER:BMP smaller than 2: 1) enhance
BMP signaling possibly by moving BMPs from the extracellular space onto receptors.
Higher levels of BMPER (ratios greater than 2: 1) block BMP signaling by increasing
endocytosis of the complex BMPER–BMP. (b) (Green) BMPER, chordin, and gremlin bind
BMP, blocking the interaction of BMP with its receptors. BMPER pro-BMP actions would
be independent of BMP interaction by physically binding and blocking chordin actions or
other mechanisms. (c) (Red) When gremlin is produced in the same cell as BMP, it can
block maturation and secretion of BMP. In addition, gremlin has proangiogenic activity
independent of BMP through interaction with a membrane receptor. BMP, bone
morphogenetic protein; BMPER, bone morphogenetic protein endothelial cell precursor-
derived regulator.
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Figure 2. Recent additions to the repertoire of regulatory mechanisms of bone morphogenetic
protein signaling
(a) BMP signaling increases expression of ALK1, which when activated by TGFβ induces
expression of the ECM component MGP. Increasing levels of MGP eventually sequester
BMP, thereby providing a negative feedback loop. (b) BMP can promote angiogenesis
through phosphorylation of Smads and Erk. Crosstalk between these two pathways occurs
through the action of inhibitory Smads. (c) GSK3 and ERK/MAPK sequential
phosphorylation at the linker domain of Smad proteins leads to its degradation, thereby
regulating BMP signaling. Wnt signaling, through inhibition of GSK3, can rescue BMP
signaling. (d) Activated Smads interact with the DROSHA component of the nuclear
miRNA processing machinery. This interaction increases the production of miRNAs
involved in vascular development. ALK1, activin receptor-like kinase 1; BMP, bone
morphogenetic protein; Cox2, cycloox-ygenase 2; ECM, extracellular matrix; ERK,
extracellular signal-regulated kinase; GSK3, glycogen synthase kinase 3; MAPK, mitogen-
activated protein kinase; MGP, matrix gamma-carboxyglutamate protein; miRNA, micro-
RNA; MyoX, myosin-X; TGFβ, transforming growth factor β.
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